Gilead Sciences (1GILD) Stock Forecast & Price Target

3 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

1GILD Analyst Ratings

Strong Buy

17 Buy

4 Hold

0 Sell

Based on 21 analysts giving stock ratings to

Gilead

Sciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

1GILD Stock 12 Month Forecast

Average Price Target

€139.69

▲(22.10% Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Gilead Sciences in the last 3 months. The average price target is €139.69 with a high forecast of €155.40 and a low forecast of €107.99. The average price target represents a 22.10% change from the last price of €114.40.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"92":"€92","108":"€108","124":"€124","140":"€140","156":"€156"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":155.39770047,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€155.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":139.68696060684212,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€139.69</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":107.98823253,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€107.99</span>\n  </div></div>","useHTML":true}}],"tickPositions":[92,108,124,140,156],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,127.265,129.4290538823077,131.59310776461538,133.75716164692307,135.92121552923078,138.08526941153846,140.24932329384615,142.41337717615383,144.57743105846154,146.74148494076923,148.9055388230769,151.0695927053846,153.2336465876923,{"y":155.39770047,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,127.265,128.22053543129556,129.1760708625911,130.13160629388665,131.0871417251822,132.04267715647774,132.99821258777328,133.95374801906883,134.90928345036437,135.86481888165994,136.8203543129555,137.77588974425103,138.73142517554658,{"y":139.68696060684212,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,127.265,125.78217173307692,124.29934346615384,122.81651519923076,121.3336869323077,119.85085866538462,118.36803039846154,116.88520213153846,115.40237386461538,113.9195455976923,112.43671733076923,110.95388906384616,109.47106079692308,{"y":107.98823253,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":93.312,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.794,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.236,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.843,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.259,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.602,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.773,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.754,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.029,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.187,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.124,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.53,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.265,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€155.40

Average Price Target€139.69

Lowest Price Target€107.99

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Michael Yee

UBS

€153.64

Buy

34.30%

Upside

Reiterated

09/24/26

Michael Yee Reiterates Buy on Gilead, Highlighting Yeztugo-Driven HIV Growth and Maintaining Unchanged $175 Price Target

Morten Herholdt

HSBC

€136.08→€153.64

Buy

34.30%

Upside

Reiterated

09/10/26

Gilead price target raised to $175 from $155 at HSBCGilead price target raised to $175 from $155 at HSBC

Brian Abrahams

RBC Capital

€107.99

Hold

-5.60%

Downside

Reiterated

09/09/26

RBC Capital Keeps Their Hold Rating on Gilead Sciences (GILD)

Courtney Breen

Bernstein

€140.47

Buy

22.79%

Upside

Reiterated

09/07/26

Gilead Sciences (GILD) Receives a Buy from Bernstein

Salim Syed

Mizuho Securities

€149.25

Buy

30.47%

Upside

Reiterated

08/31/26

Analysts Offer Insights on Healthcare Companies: Vera Therapeutics (NASDAQ: VERA) and Gilead Sciences (NASDAQ: GILD)

Gregory Renza

Truist Financial

―

Buy

―

Reiterated

08/28/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Louise Chen

Scotiabank

€155.4

Buy

35.84%

Upside

Reiterated

08/28/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Agilon Health (NYSE: AGL) and Gilead Sciences (NASDAQ: GILD)

Evan Seigerman

BMO Capital

€152.76

Buy

33.53%

Upside

Reiterated

08/27/26

Analysts Are Bullish on These Healthcare Stocks: Globus Medical (GMED), Biohaven Ltd. (BHVN)

Terence Flynn

Morgan Stanley

€144.86

Buy

26.63%

Upside

Reiterated

08/20/26

Analysts Offer Insights on Healthcare Companies: AC Immune SA (NASDAQ: ACIU) and Gilead Sciences (NASDAQ: GILD)

Emily Field

Barclays

€127.3

Hold

11.28%

Upside

Reiterated

08/13/26

Gilead Sciences (GILD) Gets a Hold from Barclays

Chris Schott

J.P. Morgan

€140.47

Buy

22.79%

Upside

Reiterated

08/06/26

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Staar Surgical (NASDAQ: STAA) and Elanco Animal Health (NYSE: ELAN)

Michael Okunewitch

Maxim Group

€144.86

Buy

26.63%

Upside

Reiterated

08/06/26

Gilead: Strong HIV and Oncology Growth Underpins Reiterated Buy Rating and Unchanged $165 Price Target

Joseph Stringer

Needham

€149.25

Buy

30.47%

Upside

Reiterated

08/05/26

Gilead Buy Rating Reaffirmed on Strong HIV-Driven Growth and Raised Revenue Outlook; $170 Price Target Maintained

Mohit Bansal

Wells Fargo

€144.86

Buy

26.63%

Upside

Assigned

08/05/26

Gilead Sciences (GILD) Gets a Buy from Wells Fargo

Umer Raffat

Evercore ISI

―

Buy

―

Reiterated

08/05/26

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Beam Therapeutics (NASDAQ: BEAM)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Michael Yee

UBS

€153.64

Buy

34.30%

Upside

Reiterated

09/24/26

Michael Yee Reiterates Buy on Gilead, Highlighting Yeztugo-Driven HIV Growth and Maintaining Unchanged $175 Price Target

Morten Herholdt

HSBC

€136.08→€153.64

Buy

34.30%

Upside

Reiterated

09/10/26

Gilead price target raised to $175 from $155 at HSBCGilead price target raised to $175 from $155 at HSBC

Brian Abrahams

RBC Capital

€107.99

Hold

-5.60%

Downside

Reiterated

09/09/26

RBC Capital Keeps Their Hold Rating on Gilead Sciences (GILD)

Courtney Breen

Bernstein

€140.47

Buy

22.79%

Upside

Reiterated

09/07/26

Gilead Sciences (GILD) Receives a Buy from Bernstein

Salim Syed

Mizuho Securities

€149.25

Buy

30.47%

Upside

Reiterated

08/31/26

Analysts Offer Insights on Healthcare Companies: Vera Therapeutics (NASDAQ: VERA) and Gilead Sciences (NASDAQ: GILD)

Gregory Renza

Truist Financial

―

Buy

―

Reiterated

08/28/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Louise Chen

Scotiabank

€155.4

Buy

35.84%

Upside

Reiterated

08/28/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Agilon Health (NYSE: AGL) and Gilead Sciences (NASDAQ: GILD)

Evan Seigerman

BMO Capital

€152.76

Buy

33.53%

Upside

Reiterated

08/27/26

Analysts Are Bullish on These Healthcare Stocks: Globus Medical (GMED), Biohaven Ltd. (BHVN)

Terence Flynn

Morgan Stanley

€144.86

Buy

26.63%

Upside

Reiterated

08/20/26

Analysts Offer Insights on Healthcare Companies: AC Immune SA (NASDAQ: ACIU) and Gilead Sciences (NASDAQ: GILD)

Emily Field

Barclays

€127.3

Hold

11.28%

Upside

Reiterated

08/13/26

Gilead Sciences (GILD) Gets a Hold from Barclays

Chris Schott

J.P. Morgan

€140.47

Buy

22.79%

Upside

Reiterated

08/06/26

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Staar Surgical (NASDAQ: STAA) and Elanco Animal Health (NYSE: ELAN)

Michael Okunewitch

Maxim Group

€144.86

Buy

26.63%

Upside

Reiterated

08/06/26

Gilead: Strong HIV and Oncology Growth Underpins Reiterated Buy Rating and Unchanged $165 Price Target

Joseph Stringer

Needham

€149.25

Buy

30.47%

Upside

Reiterated

08/05/26

Gilead Buy Rating Reaffirmed on Strong HIV-Driven Growth and Raised Revenue Outlook; $170 Price Target Maintained

Mohit Bansal

Wells Fargo

€144.86

Buy

26.63%

Upside

Assigned

08/05/26

Gilead Sciences (GILD) Gets a Buy from Wells Fargo

Umer Raffat

Evercore ISI

―

Buy

―

Reiterated

08/05/26

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Beam Therapeutics (NASDAQ: BEAM)

Stocks with the Highest Top Analyst Consensus in the General Sector

STDNStandard Nuclear

SKHYSK Hynix

ITGITG Inc. Class A

LIMENeutron Holdings, Inc.

EROCERock

Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Gilead Sciences

3 Months

Courtney BreenBernstein

Success Rate

16/20 ratings generated profit

Average Return

+7.45%

Copying Courtney Breen's trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +7.45% per trade.

1 Year

Geoff MeachamCiti

Success Rate

25/25 ratings generated profit

Average Return

+28.45%

Copying Geoff Meacham's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +28.45% per trade.

2 Years

Chris SchottJ.P. Morgan

Success Rate

25/25 ratings generated profit

Average Return

+52.73%

Copying Chris Schott's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +52.73% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1GILD Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 1GILD has received 35 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. 1GILD average Analyst price target in the past 3 months is 139.69.

Each month's total comprises the sum of three months' worth of ratings.

1GILD Financial Forecast

1GILD Earnings Forecast

Next quarter’s earnings estimate for 1GILD is €1.83 with a range of €1.64 to €2.03. The previous quarter’s EPS was -€5.83. 1GILD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year 1GILD has Performed in-line its overall industry.

1GILD Sales Forecast

Next quarter’s sales forecast for 1GILD is €6.70B with a range of €6.49B to €6.87B. The previous quarter’s sales results were €6.75B. 1GILD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year 1GILD has Performed in-line its overall industry.

1GILD Stock Forecast FAQ

What is IT:1GILD’s average 12-month price target, according to analysts?

Based on analyst ratings, Gilead Sciences’s 12-month average price target is 139.69.

What is IT:1GILD’s upside potential, based on the analysts’ average price target?

Gilead Sciences has 22.10% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Gilead Sciences a Buy, Sell or Hold?

Gilead Sciences has a consensus rating of Strong Buy, which is based on 17 buy ratings, 4 hold ratings and 0 sell ratings.

What is Gilead Sciences’s share price target?

The average share price target for Gilead Sciences is 139.69. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €155.40 ,and the lowest forecast is €107.99. The average share price target represents 22.10% Increase from the current price of €114.4.

What do analysts say about Gilead Sciences?

Gilead Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of Gilead Sciences?

To buy shares of IT:1GILD, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Gilead Sciences (1GILD) Stock Forecast & Price Target

1GILD Analyst Ratings

1GILD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Gilead Sciences

1GILD Analyst Recommendation Trends

1GILD Financial Forecast

1GILD Earnings Forecast

1GILD Sales Forecast

1GILD Stock Forecast FAQ

Detailed List of Analyst Forecasts